AMG 557 is a fully human monoclonal antibody that binds to B7 related protein (B7RP-1) that is being evaluated for its ability to prevent functional interaction with inducible co-stimulator (ICOS) on activated T cells.  Enhanced ICOS activity may lead to inappropriate and pathologic T and B cell responses associated with autoimmunity.  Disrupting the ICOS-B7RP-1 pathway with AMG 557 is being investigated for its potential utility in autoimmune diseases such as SLE.

This information is current as of November 5, 2008. Amgen’s product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen’s most recent Form 10-K and in Amgen’s periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.